"Pancreatic enzymes (medication)"

absorption in patients with SBS. The impact of pancreatic enzyme replacement treatment on enteral absorption has not been studied in this population and was the primary aim of this study. This was an interventional study in 11 subjects (6 pediatric subjects ages 4.0-17.9 years, 5 adult subjects 18-75 years) that compared enteral absorption in each subject before and after pancreatic enzyme medication (Creon). Coefficient of fat absorption (CFA) and coefficient of nitrogen absorption (CNA) were used as markers of enteral absorption of fat and protein, respectively. There was no statistically significant mean change in CFA and CNA before and after pancreatic enzyme medication therapy. Six subjects demonstrated an increase in CFA and 8 subjects demonstrated an increase in CNA after the use

), despite medical therapy, acute systemic inflammation (erythrocyte sedimentation rate > 30 mm within the first hour/ C-reactive protein > 1,0 mg/dl), antithrombin-III deficiency in case of thrombocytopenia (< 100000 per ml): pathologic clotting time, acute pancreatitis with elevated pancreas enzymes * Medical History: heart attack within the last 6 weeks, intracerebral bleeding or neurosurgical operation

).Condition or disease Intervention/treatment Phase Cystic Fibrosis Exocrine Pancreatic Insufficiency Drug: Liprotamase Drug: Placebo Phase 3 Detailed Description: This trial is divided into four distinct periods: 1. Baseline Period during which each patient is taken off pancreatic enzyme medications. 2. An Open-Label Treatment Period during

) methods as potential screening or diagnostic tests for reduced exocrine pancreatic function or pancreatic insufficiency (RPF/PI). A further objective is to determine the test responses before and after pancreatic enzyme medication administration (Creon36™) in the patients with chronic pancreatitis (CP).Condition or disease Intervention/treatment Phase Chronic Pancreatitis Drug: Creon36™ Phase 2 Detailed Description: Reduced exocrine pancreatic function or pancreatic insufficiency (RPF/PI) contributes to poor clinical outcome in a number of diseases and conditions. The incidence, mechanism and substantial adverse clinical outcomes of pancreatic insufficiency (PI) are well known in patients with cystic fibrosis (CF), and the life sustaining role of pancreatic enzyme medication

nutrition for at least three months * age 4 years to 65 years * usual state of health for the past two weeks with no medication changes * able to participate in a study for about four weeks with four study visits * able to take pancreatic enzyme medication orallyExclusion Criteria: * significant disease other than short bowel syndrome affecting the gastrointestinal tract that impacts absorption